Todd Usen joined Minerva Surgical as President & CEO on January 3, 2023. Prior to Minerva Todd served as CEO at Activ Surgical, where he oversaw the FDA clearance of its ActivSight technology, as well as leading four Series fundraising rounds totaling over $92M.

Todd came to Activ Surgical after serving as the President of the Medical Systems Group at Olympus Corporation of the Americas, where he helped lead the expansion from 6 medical divisions to 11 in 3.5 years. Prior to joining the Olympus Corporation, Todd held the position of President, Orthopedics, at Smith and Nephew, overseeing the Total Joint, Sports Medicine and Trauma divisions.

Todd has held several other vital positions for Smith and Nelson including Senior Vice President and General Manager, Joint Reconstruction; Senior Vice President, Sports Medicine; and Senior Vice President, Endoscopy.

Prior to Smith and Nephew, Todd worked for Boston Scientific as the Vice President of Sales for the Neurovascular Division, Director of Endoscopy Sales, and Global Manager of Field Development.

Todd completed his MBA at Pepperdine University and graduated Magna Cum Laude from the Isenberg School at the University of Massachusetts, While at UMASS he played baseball and was recognized and inducted into the “Outstanding College Students of America” and the Golden Key National Honor Society.

Joel R. Jung - Chief Financial Officer. Prior to joining our company, Mr. Jung served as the CFO at several life sciences companies including Counsyl, Inc. (acquired by Myriad Genetics, Inc.) from July 2016 to September 2018, Bionano Genomics, Inc. from February 2014 to June 2016, AgraQuest, Inc. (acquired by Bayer CropScience) from February 2010 to December 2012, and Celera Corporation from June 2008 to April 2009. He also served as Vice President of Finance with Bayer CropScience from December 2012 to June 2013, Applera Corporation-Celera Group from June 2006 to June 2008, and Chiron Corporation (acquired by Novartis) from September 1999 to April 2003, and Vice President and Treasurer of Chiron Corporation from April 2003 to July 2006. Mr. Jung holds a B.S. Degree in Aeronautical Engineering from Purdue University, and an M.B.A. from the Haas School of Business at the University of California, Berkeley.

Kaile was raised in Southern California and attended University of Connecticut where she played Varsity Women’s Tennis. Post graduation, she began her career with General Electric as a member of the Global Leadership Development Program where she lived in various countries for 2+ years and studied at Crotonville. Upon graduation, she set forth into a 20+ year career in the healthcare industry and has held significant executive leadership positions for many highly acclaimed corporations such as Boston Scientific, Intuitive Surgical, GE Healthcare, Philips Healthtech, and Change Healthcare. In addition to her career, she is a Co-Founder of the MAT Foundation, a non-profit organization whose mission is to eradicate late stage diagnosis of gynecological cancer. She has also enjoyed advisory positions with private equity firms focused on restructuring, has sat as a board member for both private organizations and non-profits and was most recently leading a large scale restructuring of an organization focused on infant health, as CEO and Member of the Board of Infinant Health.

Kaile is a mother of 2 children, Geralyn (9) and Colton (7) and lives in Westport, Connecticut. . “ The world needs strong women. Women who will lift others up. Those who live bravely. Women who are both tender and fierce. Women are powerful when they are free to become themselves. Women give of themselves, their bodies, to bring forward the next generation; but in time, that same engine that brought forward life, may negatively impact her own. We strive to set her free to live her best life.”

Dominique J. Filloux serves as our Chief Operating Officer of our company. He has held various positions with the Company since 2010, including Vice President of Research & Development and Operations, and Chief Technology Officer. Prior to joining our company, he served as Director of Research & Development at Endovascular Technologies (acquired by Guidant) from 1992 to 2000, Vice President of Operations at Ventrica, Inc. from 2001 to 2004, Vice President of Research & Development and Operations at Cierra Inc. from 2004 to 2007, and Vice President of Research & Development at Arstasis, Inc. from 2007 to 2010. He holds a B.S. Degree in Applied Mechanics from the University of California at San Diego, and an M.B.A. from Santa Clara University, Leavey School of Business.

Eugene V. Skalnyi, M.D. joined the company in January 2011. Prior to that, Dr. Skalnyi served as Vice President of Medical Affairs for several companies, including Sierra Surgical Technologies, Cytyc Surgical Products (acquired by Hologic, Inc.), Novacept Inc. (acquired by Cytyc Corporation), other. In addition, he served as a Medical Advisor and/or member of Board of Directors for various companies, including Meditrina, Inc., CorRx, Inc., IoGyn, Inc. (acquired by Boston Scientific), and Pulse Therapeutic Technology, Inc. Dr. Skalnyi continues to be academically active by serving on the Editorial Advisory Board for the Journal of Minimally Invasive Gynecology. Dr. Skalnyi received his Medical Degree from Moldova State University of Medicine and Pharmacy “Nicolae Testemitanu” in 1988 and sub-specialized in Advanced Operative Endoscopy in 1990.

Arleen Felt has over 30 years of experience in the Medical Device industry in both Quality Assurance and Operations. Arleen has vast experience working with large, multi-national corporations as well as smaller, start-up device companies. Prior to joining Minerva Surgical in 2021 Arleen held management positions at ZipLine Medical (acquired by Stryker), EarLens, Arqos Surgical, Sierra Surgical, Cytyc Surgical (Acquired by Hologic), Abbott Labs/Hospira, and LifeScan, a Johnson and Johnson Company. In addition, Arleen served as a QA consultant for Minerva Surgical in 2011 during the early development of the Minerva ES system and also worked closely with IOGYN on the development of the Symphion system prior to the acquisition of the product by Boston Scientific. She holds a B.S. Degree in Applied Mathematics from the University of California, Berkeley, and an M.B.A from Santa Clara University. She is also an ASQ certified Biomedical Quality Auditor.

Joanne Long serves as Vice President, Corporate Controller of Minerva Surgical since February 2021. She brings 10 years of experience in accounting, with a focus on health care and medical technology industry. Prior to joining Minerva Surgical, Joanne was Vice President, Corporate Controller at Carbon Health Technologies. She also held financial leadership positions at two other health care companies including Counsyl, Inc., which was acquired by Myriad Genetics, Inc. Joanne began her career in public accounting, spending 6 years at KPMG, LLP, and earned her B.S. in Accounting from University of Queensland, Australia and is an inactive Certified Public Accountant.

Wendy Bowman serves as our VP, Human Resources; she joined us in 2015 as Director of HR. She brings 20 years of in-house and consulting HR experience in large companies, small emerging companies, and venture capital firms. Most recently, Ms. Bowman has been an HR Consultant with Christine Mathews Consulting advising leadership teams and building out HR strategies for business growth. Previously, she held roles at SurgRx (acquired by Ethicon Endo-Surgery, a Johnson & Johnson company) and Procter & Gamble. She received a B.S. in Business Administration from University of Costa Rica.

Klyde Kanegawa serves as our Vice President of Manufacturing, He joined us in 2011 as Director of Operations. Prior to joining our company, he served as Director of Manufacturing Engineering for three companies including SpineView Inc. from August 2009 to October 2011, SurgRx Inc. (acquired by Ethicon Endo-Surgery) from April 2006 to July 2009, and Novacept Inc. (acquired by Cytyc Corporation) from July 2002 to April 2006. He has also served in various engineering roles at ArthroCare Corporation, Cardiac Pathways Corporation, Guidant Corporation, ReSound Corporation, Life Enhancement Technologies Inc., and Life Support Systems Inc. Mr. Kanegawa holds a B.S. Degree in Mechanical Engineering from University of California at Davis and an M.B.A. from Santa Clara University.

Todd Usen joined Minerva Surgical as President & CEO on January 3, 2023. Prior to Minerva Todd served as CEO at Activ Surgical, where he oversaw the FDA clearance of its ActivSight technology, as well as leading four Series fundraising rounds totaling over $92M.

Todd came to Activ Surgical after serving as the President of the Medical Systems Group at Olympus Corporation of the Americas, where he helped lead the expansion from 6 medical divisions to 11 in 3.5 years. Prior to joining the Olympus Corporation, Todd held the position of President, Orthopedics, at Smith and Nephew, overseeing the Total Joint, Sports Medicine and Trauma divisions.

Todd has held several other vital positions for Smith and Nelson including Senior Vice President and General Manager, Joint Reconstruction; Senior Vice President, Sports Medicine; and Senior Vice President, Endoscopy.

Prior to Smith and Nephew, Todd worked for Boston Scientific as the Vice President of Sales for the Neurovascular Division, Director of Endoscopy Sales, and Global Manager of Field Development.

Todd completed his MBA at Pepperdine University and graduated Magna Cum Laude from the Isenberg School at the University of Massachusetts, While at UMASS he played baseball and was recognized and inducted into the “Outstanding College Students of America” and the Golden Key National Honor Society.

Jill D. Anderson has served as a member of our board of directors since May 2021. Ms. Anderson is a healthcare executive with more than 25 years of experience leading the innovation, development, and commercialization of medical devices. Ms. Anderson was the co-founder and Chief Executive Officer of Cianna Medical, Inc. from January 2008 until its acquisition by Merit Medical Systems, Inc. in November 2018. She also served as President of BioLucent, Inc. from May 2001 until September 2007, as Vice President, Cancer Services of Lehigh Valley Hospital and Health Network from October 1999 until May 2001, and as Vice President, Eastern Region, of Salick Health Care, Inc. from June 1989 until October 1999. Ms. Anderson also serves on the board of directors of Merit Medical Systems, Inc. (Nasdaq: MMSI) and OncoRes Medical, LLC, and in the past served on the boards of Cianna Medical, Inc. and WDT Acquisition Corporation d/b/a Solis Mammography. She is a member of the Women Business Leaders in Healthcare and a Leadership Fellow of the National Association of Corporate Directors. She earned a B.A. in Finance, Magna Cum Laude, as well as an M.B.A. from Temple University.

Niquette Hunt has served as a member of our board of directors since June 2021. Ms. Hunt founded Candesant Biomedical in March 2016, and serves as its President and Chief Executive Officer. From 2009 to 2016, Ms. Hunt served as the Senior Vice President of Commercial Development for Revance Therapeutics. Ms. Hunt has served on the board of directors for Soliton, Inc. (Nasdaq: SOLY) since October 2020. Ms. Hunt holds an A.B. degree in Organizational Dynamics from Stanford University.

Ali Behbahani, M.D. has served as a member of our board of directors since May 2011. Dr. Behbahani serves as a General Partner of New Enterprise Associates (NEA), a global venture capital firm that focuses on development of technologies that drive global innovation. He is on the healthcare team at NEA, and specializes in investments in the biopharmaceutical and medical device sectors. Dr. Behbahani also serves on the board for several private and public companies, including Adaptimmune Therapeutics plc, Cardionomic, Inc., CRISPR Therapeutics AG, CVRx, Inc., Genocea Biosciences, Inc., Ivantis, Inc., Monte Rosa Therapeutics GmbH, Nkarta Inc., Oyster Point Pharma Inc., and Black Diamond Therapeutics, Inc. Dr. Behbahani holds B.S. Degrees with distinction in Biomedical Engineering, Electrical Engineering, and Chemistry from Duke University. He earned an M.D. from The University of Pennsylvania School of Medicine and an M.B.A. from The University of Pennsylvania Wharton School, where he graduated with Honors.

Catherine Coste has served as a member of our board of directors since February 2021. Ms. Coste retired from Deloitte and Touche LLP in 2020, where she was a senior partner and served as one of Deloitte’s Life Sciences Industry Executive Leaders. She spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Coste also has extensive public company board experience, often attending multiple board committee meetings per month, and currently serves as a director and audit committee chair for Biomerica, Inc. Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls, and corporate governance. Ms. Coste is a Certified Public Accountant. Ms. Coste earned her B.A. in Business Administration, Accounting, from California State University, Hayward.

Derrick Sung, Ph.D. has served as a member of our Board of Directors since July 2022. Dr. Sung has served as the Chief Financial Officer of Pulmonx Corporation since 2019. From 2015 to 2019, Dr. Sung served as the Executive Vice President of Strategy and Corporate Development for iRhythm Technologies, Inc., a digital healthcare and medical technology company. From 2008 to 2015, Dr. Sung was the senior equity research analyst covering the medical devices sector for Sanford C. Bernstein & Co., LLC, a subsidiary of AllianceBernstein L.P. From 2004 to 2008, he served as Director of Marketing and Business Development in the Neuromodulation division of Boston Scientific Corporation. From 2000 to 2004, Dr. Sung was a management consultant at The Boston Consulting Group, and he began his career as an R&D engineer for Guidant Corporation. Dr. Sung holds a Ph.D. in Bioengineering from U.C. San Diego, an M.B.A. from San Diego State University and a B.S. in Mechanical Engineering from Stanford University.

Uri Geiger brings extensive entrepreneurial, management and investment know-how, having created and built many successful medical device enterprises.

Prior to founding Accelmed, Dr. Geiger founded served as CEO of Exalenz Bioscience Ltd. (TASE:EXEN), developer of an innovative breath-based technology for diagnosing liver and gastrointestinal disorders which Dr. Geiger took public in 2007 and later sold to Meridian (NASDAQ: VIVO). Prior to Exalenz, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components, sold in 2003 to MEMSCAP (EuroNext: MEMS). Dr. Geiger is also the founding partner of Dragon Variation Fund, one of Israel’s first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of capital markets and significant experience, which he put to use after returning to Israel in 1999.

Dr. Geiger was formerly an adjunct professor at the Recanati Business School at Tel Aviv University, where he lectured on private equity and venture capital. He is the author of the books: Startup Companies and Venture Capital (Tel Aviv University Press, 2001) and From Concept to Wall Street (Financial Times – Prentice Hall, 2003). He earned his doctorate from New York’s Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as a major in the Israeli Air Force.

Dr. Geiger is also involved in an extensive philanthropic activity and is the Founder & Chairman of Friends of Poriya Medical Center in the US.

Dan has over 25 years of experience in medical technology finance, investment banking, and private equity. Dan was the Israeli GM of China-based Fosun Pharma, and a principal at France-based Credit Agricole. Dan holds an MBA from ESSEC MBA, a BSc in Computer Sciences, a BA in Mathematics, and graduate studies in Biology.